Adipotide vs Semaglutide
A side-by-side research comparison of Adipotide and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adipotide | Semaglutide |
|---|---|---|
| Full name | Adipotide (FTPP / Prohibitin-Targeting Peptide) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound (preclinical) | FDA Approved |
| Mechanism | A fusion of a prohibitin-targeting peptide and a pro-apoptotic sequence. It binds prohibitin on the vasculature that feeds white fat, inducing apoptosis of those blood vessels, which starves fat cells and causes them to be resorbed. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | ~2.6 kDa | 4,114 Da |
| Half-life | Short (hours) | 7 days (168 hours) |
| Bioavailability | Subcutaneous injection | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | Not established for human use | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Research protocols only | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
Adipotide reported benefits
- Rapid targeted white-fat reduction (animal models)
- Weight loss without appetite suppression
- Reversal of metabolic markers in obese primates
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.